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Background: Amrubicin and cisplatin are active in the treatment of
small cell lung cancer (SCLC), and carboplatin is an analogue of
cisplatin with less nonhematological toxicity. The appropriate dose
of amrubicin and carboplatin combination chemotherapy for previ-
ously untreated patients with extensive-disease (ED) SCLC has not
been established.
Purpose: To determine the maximum-tolerated dose and dose-
limiting toxicity (DLT) of amrubicin and carboplatin in ED-SCLC.
Patients and methods: Eligibility criteria were chemotherapy-naive
ED-SCLC patients, performance status 0–1, age 75, and adequate
hematological, hepatic, and renal function. Patients received esca-
lating amrubicin doses under a fixed target area under the curve
(AUC) 5 of carboplatin (Chatelut formula). Amrubicin and carbo-
platin were administered by intravenous (IV) infusion on days 1, 2,
and 3, and day 1, respectively. The initial dose of amrubicin was 30
mg/m2, and the dose was escalated to 35 and 40 mg/m2.
Results: Sixteen patients were enrolled and 15 eligible patients were
evaluated. One of six patients in level 1, one of six in level 2, and
three of three in level 3 experienced DLTs. The presentation of
DLTs included neutropenia, leukopenia, thrombocytopenia, febrile
neutropenia, and liver dysfunction. Evaluation of responses were
two complete response, nine partial response, three stable disease,
and one progressive disease (response rate 73%), and the median
survival time was 13.6 months. The maximum-tolerated doses of
amrubicin and carboplatin were determined as 40 mg/m2 and AUC 5.
A dose of 35 mg/m2 amrubicin and carboplatin AUC 5 was recom-
mended in this regimen.
Conclusions: This regimen is associated with an acceptable toler-
ability profile, and warrants evaluation in the phase II setting.
Key Words: Amrubicin, Carboplatin, Small cell lung cancer, Phase
I study.
(J Thorac Oncol. 2009;4: 741–745)
Lung cancer is the leading cause of cancer death worldwide.It is also the leading cause of death in Japan with 63,255
deaths (19.2% of all cancer deaths) in 2006.1 Of all lung
cancer cases, approximately 20% is small cell lung cancer
(SCLC).2 Despite this cancer being highly responsive to
chemotherapy initially, most of patients will ultimately re-
lapse and die of recurrent disease within 2 years.3 Recently,
combination chemotherapy with irinotecan and cisplatin for
extensive-disease (ED) SCLC produced equal or better sur-
vival with increased toxicities compared with etoposide and
cisplatin, the worldwide standard regimen since 1981.4–6 As
the therapy provided 2-year survival rates of only 8.0 to
19.5%, with a median survival time (MST) of 9.3 to 12.8
months, new and more effective agents are clearly needed
against SCLC.
Amrubicin is a completely synthetic anthracycline de-
rivative characterized by a 9-amino group and a simple sugar
moiety. The chemical structure and acute toxicity of amrubi-
cin are similar to that of doxorubicin7,8; however, amrubicin
shows almost no cardiotoxicity.9,10 Amrubicin alone and
combination chemotherapy with cisplatin exhibited high re-
sponse rates of 75.8% and 87.8% and MSTs of 11.7 and 13.6
months in previously untreated ED-SCLC, respectively.11,12
Carboplatin is a platinum derivative with less renal
toxicity and less nausea and vomiting than cisplatin,13 and
which has been combined with other newer agents in chemo-
therapy for SCLC.14 Pharmacodynamic studies have been
performed to predict clearance (CL) and administer the appro-
priate dose of carboplatin in individual patients.15–17 The pre-
ceding study evaluated the Chatelut formula, and reported that
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predicted carboplatin CL was closely correlated with the
actual CL, and the actual area under the curves (AUCs) of
carboplatin nearly reached the target AUC of 5.18
Based on these results, a phase I study of amrubicin and
carboplatin was conducted for SCLC. The main objective of
this study was to determine the maximum-tolerated dose
(MTD) of this combination chemotherapy.
PATIENTS AND METHODS
The study protocol was reviewed and approved by the
Ethics Committee of each institution, and written informed
consent was obtained from all study participants. This study
is an independent collaborative (not sponsored) group study.
Patients and Evaluation
Eligibility criteria for patients in this study included the
following: a histologically and/or cytologically confirmed
diagnosis of SCLC; extensive stage disease19; no prior che-
motherapy or radiotherapy; age 75 years; Eastern Cooper-
ative Oncology Group performance status 1; life expect-
ancy greater than 12 weeks; adequate bone marrow function
(leukocyte count4000/l, platelet count10.0 104/l, and
hemoglobin level10.0 g/dl); serum bilirubin level1.5 mg/dl;
alanine aminotransferase (ALT) and aspartate transaminase
(AST) levels2 times the normal upper limit; serum creatinine
level less than the normal upper limit; and no medical problems
severe enough to prevent compliance with the protocol.
Treatment and Dose Escalation
Under a fixed-target AUC of 5 mg/min/ml for carbo-
platin on day 1, the starting dose of amrubicin was 30 mg/m2
administered on days 1 to 3. The dose of carboplatin was
determined by multiplying the target AUC of 5 by the
carboplatin CL, which was predicted with the Chatelut for-
mula17 using the Jaffe´ method to measure serum creatinine.20
The values of serum creatinine obtained using the enzymatic
method (X) were converted by the Jaffe´ method (Y) using the
formula Y  0.97X  0.27. Then, the estimated CL (ml/min)
was calculated as follows: CL  0.134  weight  (218 
weight  (1  0.00457  age)  (1  0.314  sex)) 
116.4 104/(sCr 0.28) (with weight in kg, age in years, and
sex 0 if male and sex 1 if female). In Japanese institutions,
the measurement method of serum creatinine was changed to the
enzymatic method. The dose of amrubicin was increased by 5
mg/m2 as shown in Table 1. Carboplatin was administered
during a 60-minute intravenous (IV) infusion of 250 ml of 5%
dextrose. Amrubicin was diluted in 20 ml of normal saline
and administered as an IV injection during a drip infusion of
normal saline. Intrapatient dose escalation was not allowed.
Granulocyte colony-stimulating factor was administrated
when the neutrophil count reached 1000/l and discontin-
ued when the count recovered to5000/l. The next cycle at
each level commenced after leukocyte and platelet counts
reached at least 3000/l and 100,000/l, respectively. In
patients showing a response, this chemotherapy was repeated
every 3 weeks for four cycles.
The dose-limiting toxicity (DLT) was evaluated at the
first cycle and defined as follows: grade 4 leukopenia or
neutropenia lasting 4 days or more; grade 3 febrile neutrope-
nia; platelets20,000/l; grade 3 or worse nonhematological
toxicity except for nausea, vomiting, anorexia, fatigue, hypo-
natremia, and infection. For dose escalation, three patients
were enrolled at each dose level, and the dose was escalated
to the next level when none of patients experienced DLT.
When two or more patients experienced DLT, the dose level
was defined as the MTD. When one of three patients expe-
rienced DLT, an additional three patients were treated at the
same level. When none of the additional patients experienced
DLT, the dose was escalated to the next level. When one or
more of the additional patients experienced DLT, the dose level
was also defined as the MTD. The recommended dose (RD) of
this regimen for a phase II study was defined as the previous
level below the MTD. Dose escalation was determined based
only on the data from the first course of chemotherapy. Leuko-
cytes3000/l and platelets10 104/l were mandatory to
commence the second cycle of treatment, and if levels fell
below these limits, the second cycle was postponed until the
counts recovered. Doses of amrubicin and carboplatin were
reduced to 80% when DLT occurred during the first treatment
cycle.
Toxicity and Response Evaluation
Eligibility, assessability, and tumor responses were
determined by external reviewers. Drug toxicity was graded
according to the National Cancer Institute Common Toxicity
Criteria, Version 2.0.21 Before the first cycle, a blood cell
count, urinalysis, and biochemistry tests were performed to
assess renal and hepatic function, and electrolytes. This
monitoring was repeated during treatment, whereas other
investigations were repeated as necessary, to evaluate marker
lesions. After the completion of treatment, each disease was
assessed and tumors restaged. Tumor response was classified
according to Response Evaluation Criteria in Solid Tumors
(RECIST) and tumor markers were excluded from the crite-
ria.22 Complete response was defined as the complete disap-
pearance of all clinically detectable tumors for at least 4
weeks and no new lesions. Partial response was defined as at
least a 30% decrease in the sum of the longest diameters of
target lesion, taking as reference the baseline sum of the
longest diameters, the required nonprogression in nontarget
lesions, and no new lesions for at least 4 weeks. Stable
disease included regression of target lesions insufficient to
meet the criteria for partial response, a 20% increase in the
sum of the longest diameters of target lesion, taking as reference
the smallest sum of the longest diameters recorded since the start
of treatment, the required nonprogression in nontarget lesions,
and no new lesions for at least 6 weeks. Progressive disease
indicated a 20% increase in the sum of the longest diame-
TABLE 1. Dose Escalation Schedule
Dose
Level
No. of
Patients
Amrubicin
(mg/m2)
Carboplatin Target
AUC (mg/min/ml)
1 6 30 5
2 6 35 5
3 3 40 5
AUC, area under the concentration-time curve.
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ters of the target lesion, taking as reference the smallest sum
of the longest diameter recorded since the start treatment
and/or unequivocal progression of existing nontarget lesions
and/or appearance of new lesions. The evaluation of objective
tumor response for all patients was performed by external
reviewers.
RESULTS
Sixteen patients were enrolled and 15 patients treated in
this trial, between July 2003 and August 2007. One patient
did not receive the protocol therapy because radiotherapy was
needed after enrollment. All patients who received the
planned therapy were evaluated for toxicity, response, and
survival. The baseline patient characteristics are shown in
Table 2.
Treatment Administration
A total of 49 cycles of this therapy were administered
with a median of 4 cycles per patient: 1 cycle in 2 patients
(13%), 2 cycles in 2 (13%), 3 cycles in 3 (20%), 4 cycles in
6 (40%), and 5 cycles in 2 (13%). Six patients were treated at
dose levels 1 and 2, and 3 patients were treated at dose level 3.
Dose Escalation
At level 1, one of the three original patients experi-
enced DLTs (grade 4 neutropenia lasting 10 days, grade 4
leukopenia lasting 7 days, and grade 4 AST/ALT elevation),
but none of the three additional patients experienced DLT. At
level 2, one of the three original patients experienced DLT
(thrombocytopenia20,000/ml), but none of three additional
patients experienced DLT. At level 3, all three patients
experienced DLTs as follows: three patients experienced
grade 4 neutropenia lasting 4 days, one patient experienced
grade 4 leukopenia 4 days, thrombocytopenia 20,000/ml,
febrile neutropenia, and grade 3 mucositis. Level 3 was consid-
ered to be too toxic and determined to be the MTD. Therefore,
level 2 (amrubicin 35 mg/m2 and carboplatin AUC 5) was
regarded as the RD of this regimen for the phase II study.
Hematological Toxicity
The worst grades of hematological toxicities experi-
enced by each patient are listed Table 3. Leukopenia, neu-
tropenia, thrombocytopenia, and febrile neutropenia were the
principal toxicities. Of the 15 patients, 6 (40%) experienced
grade 4 hematological toxicities and 5 (33%) experienced
hematological DLTs. At dose level 1, 1 patient (17%) expe-
rienced grade 4 hematological toxicity as a DLT. At dose
level 2, 2 patients (33%) experienced grade 4 hematological
toxicity including 1 (17%) hematological DLT. At dose level
3, all 3 patients experienced grade 4 hematological toxicities
as DLTs, and one patient required platelet transfusion. Ane-
mia requiring blood transfusion was observed one patient
each at levels 1 and 2. There was one treatment-related death
due to severe hematological toxicity. In the third cycle of
dose level 3, a patient treated with 32 mg/m2 amrubicin and
carboplatin with a target AUC of 4 mg/min/ml because of
20% dose reduction experienced grade 4 leukopenia, neutro-
penia, and thrombocytopenia and grade 3 febrile neutropenia
on day 16. Despite intensive care, the patient developed
sepsis due to methicillin-resistant Staphylococcus aureus, and
died on day 23.
Nonhematological Toxicity
The worst grades of nonhematological toxicity experi-
enced by each patient are listed Table 4. Frequent nonhema-
tological adverse events included nausea, liver dysfunction
(AST and ALT elevation), and mucositis of the oral cavity. In
total, 2 patients (13%) experienced nonhematological DLTs.
At dose level 1, 1 patient experienced grade 4 liver dysfunc-
tion. At dose level 3, 1 patient experienced grade 3 mucositis
of the oral cavity.
Efficacy
All 15 patients were assessable for response. Objective
tumor response was observed in 11 patients, with an overall
response rate of 73% (95% confidence interval, 45–92%)
(Table 5). Two patients (13%) had complete response. At the
survival assessment in July 2008, 3 patients were still alive
and the other 12 patients had died. The overall survival of 15
patients is shown in Figure 1. MST was 13.6 months and the
1-year survival rate was 50.3%.
DISCUSSION
Amrubicin has shown excellent activity for the treat-
ment of previously untreated patients with ED-SCLC. In a
single agent phase II study with 45 mg/m2 amrubicin on days
1–3, the overall response rate, MST, and 1-year and 2-year
survival rates were 75.8%, 11.7 months, 48.5%, and 20.2%,
respectively.11 Because recent randomized trials of cisplatin/
etoposide have demonstrated MSTs of 9.1 to 10.2 months,4–6
this single agent might be comparable with standard combi-
TABLE 2. Patient Characteristics
Characteristics No. of Patients
Gender
Male 15
Female 0
Age (yr)
Median 67
Range 49–75
Performance status (ECOG)
0 2
1 13
Stage
IIIB 6
IV 9
No. of metastasis sites
1 10
1 5
LDH
Normal 8
Increased 7
Weight loss
5% 2
5% 13
ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase.
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nation chemotherapy. In combination with cisplatin, amrubi-
cin demonstrated promising overall response, MST, and
1-year survival rate of 87.8%, 13.6 months, and 56.1%,
respectively.12 Carboplatin is a platinum derivative with sim-
ilar activity and less nonhematologic toxicity than cisplatin.
Thus, taken together with carboplatin and the most active
single agent amrubicin, the present combination chemother-
apy for SCLC was considered to be worthwhile.
In vivo comparison between single day therapy and
repeated 5-consective-day therapy on several cell lines re-
vealed superior antitumor effects for the 5-day administration
of amrubicin.23 As for clinical, phase I trials, both day 1
therapy and 5-consecutive-day therapy every 3 weeks were
performed in patients with various types of malignant tumors
that had been treated previously.24,25 However, a clear tumor
shrinking effect was not seen. Finally, because another an-
thracycline reported higher response26 and in consideration of
its convenience for practical use, 3-consecutive-day admin-
istration every 3 weeks came to be recommended for amru-
bicin. In a phase I/II trial of previously untreated patients with
non-small cell lung cancer, the RD of single agent amru-
bicin was determined as 45 mg/m2.27 This dose was also
used in SCLC.11 In combination with cisplatin, the RD of
amrubicin was decreased to 40 mg/m2.12 In present study of
amrubicin 40 mg/m2 and carboplatin AUC 5 level, all three
patients experienced severe hematological toxicities, and it
was considered that this dose level was too toxic. The RD of
amrubicin in combination with carboplatin was determined as
35 mg/m2. In combination chemotherapy with irinotecan,
which is also a topoisomerase inhibitor, the RD of carboplatin
(50 mg/m2) is lower than cisplatin (60 mg/m2).28,18 Consid-
ering the hematological toxicity of carboplatin, it is reason-
able to lower RD level compared with cisplatin.
The principal toxicity in the present study was myelo-
toxicity. In the toxicity profile of amrubicin, neutropenia was
most severe toxicity for determining of the RD for amrubicin.
Grade 4 leukopenia, neutropenia, and thrombocytopenia oc-
curred in 12, 42, and 18% of patients treated with amrubicin
alone,11 17, 78, and 0% at the RD of amrubicin/cisplatin,12
and 0, 33, and 17% at the RD in the present study, respectively.
Although the numbers were small for the comparisons, the rate
of grade 4 neutropenia in amrubicin/cisplatin seems too high.
Recently, a phase I trial of amrubicin/carboplatin for elderly
TABLE 3. Hematological Toxicities
Dose Level No. of Patients
Anemia Leukopenia Neutropenia Plt
FN
3Gr 2 3 2 3 4 2 3 4 3 4
1 6 (1) 1 0 2 1 1 (1) 1 4 1 (1) 1 0 1 (1)
2 6 (1) 2 0 3 2 0 0 4 2 2 1 (1) 0
3 3 (3)a 3 0 0 1 2 (1) 0 0 3 (3) 1 1 (1) 1 (1)
The numbers in parentheses are the number of patients who experienced dose-limiting toxicities.
a One patient experienced grade 4 leukopenia, neutropenia, thrombocytopenia, and febrile neutropenia.
Plt, thrombocytopenia; FN, febrile neutropenia.
TABLE 4. Nonhematological Toxicities
Dose Level No. of Patients
Nausea s-AST s-ALT s-Cr Mucositis
Gr 1 >2 1 >2 1 >2 1 >2 1 >2
1 6 (1) 2 2 1 1 (1)a 0 1 (1)a 1 0 0 0
2 6 (1) 2 0 0 0 0 0 0 0 0 0
3 3 (3) 1 0 1 0 2 0 0 1 0 1 (1)b
The numbers in parentheses are the number of patients who experienced dose-limiting toxicities.
a Grade 4 toxicity.
b Grade 3 toxicity.
TABLE 5. Tumor Response
Dose Level CR PR SD PD
1 0 4 2 0
2 1 5 0 0
3 1 0 1 1
Rate (%) 13 60 27 7
Overall response 73% (95% confidence interval, 45–92%).
CR, complete response; PR, partial response; SD, stable disease; PD, progressive
disease.
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FIGURE 1. Overall survival curves of the 15 patients en-
rolled in the present study.
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patients was reported.29 The RD of amrubicin was 35 mg/m2
(but with carboplatin AUC 4), which is same as the present
study. Grade 4 neutropenia in this study at the RD29 also
occurred at high rate of 78%. Unfortunately, one patient died
due to severe hematological toxicities during the third cycle
of dose level 3. This was discussed at an investigator’s
meeting, and it was determined to decrease the dose modifi-
cation of 80 to 75% for next cycle in the phase II trial. Based
on these data, careful hematological toxicity control is essen-
tial for use of amrubicin.
In conclusion, the present phase I trial demonstrated
that the DLTs of amrubicin in combination with carboplatin
for patients with ED-SCLC were neutropenia, leukopenia,
thrombocytopenia, febrile neutropenia, liver dysfunction, and
mucositis. The RD for this regimen is 35 mg/m2 for amrubi-
cin and AUC 5 for carboplatin. Based on the present results,
a phase II trial is now ongoing for ED-SCLC.
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